|
SEC24A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.54880000000379E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.28839999996777E-06 |
| Normal-vs-Stage2 |
8.018600E-04 |
| Normal-vs-Stage3 |
6.86150000039909E-07 |
| Normal-vs-Stage4 |
1.81405999999384E-05 |
| Stage1-vs-Stage2 |
9.076200E-01 |
| Stage1-vs-Stage3 |
3.466600E-01 |
| Stage1-vs-Stage4 |
2.579600E-01 |
| Stage2-vs-Stage3 |
6.114400E-01 |
| Stage2-vs-Stage4 |
4.717600E-01 |
| Stage3-vs-Stage4 |
6.883200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.10509999995401E-06 |
| Normal-vs-AfricanAmerican |
3.530400E-02 |
| Normal-vs-Asian |
3.25919999999424E-06 |
| Caucasian-vs-AfricanAmerican |
2.898600E-01 |
| Caucasian-vs-Asian |
3.126400E-01 |
| AfricanAmerican-vs-Asian |
1.072990E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.22000000008549E-07 |
| Normal-vs-Female |
1.87029999998423E-06 |
| Male-vs-Female |
3.819800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.752500E-04 |
| Normal-vs-Age(41-60Yrs) |
1.22079999997915E-07 |
| Normal-vs-Age(61-80Yrs) |
4.93639999998852E-06 |
| Normal-vs-Age(81-100Yrs) |
1.322830E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.532400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.926380E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.637200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.357000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.505000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.213000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.834000E-01 |
| Classical-VS-Follicular |
1.050410E-02 |
| Classical-VS-Other |
5.623700E-02 |
| Classical-VS-Normal |
7.53380000000359E-05 |
| Tall-VS-Follicular |
5.892000E-01 |
| Tall-VS-Other |
1.600560E-01 |
| Tall-VS-Normal |
2.351900E-04 |
| Follicular-VS-Other |
3.080400E-01 |
| Follicular-VS-Normal |
2.27130000030051E-07 |
| Other-VS-Normal |
4.602200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.34560000031314E-07 |
| Normal-vs-N1 |
1.68889999999644E-05 |
| N0-vs-N1 |
7.393400E-01 |
|
|
